Enclomiphene and SLU-PP-332 Interaction

Avoid
Mechanism-based 53% confidence

Enclomiphene and SLU-PP-332 have a potentially harmful interaction with 53% confidence. Both Enclomiphene and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. These compounds primarily affect different organ systems.

Compound Profiles

Enclomiphene

Selective Estrogen Receptor Modulator | Testosterone & Fertility Support

Enclomiphene competitively antagonizes estrogen receptors in the hypothalamus and anterior pituitary, blocking the negative feedback of estradiol on GnRH release. This disinhibition increases pulsatile GnRH secretion, which in turn stimulates the anterior pituitary to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Half-life: ~10 hours Typical dose: 12.5-25mg oral daily pct, sexual health
estrogen receptorserotonin receptor hepatotoxicpct agentteratogenic
View full profile

SLU-PP-332

Synthetic Pan-ERR Agonist | Exercise Mimetic & Metabolic Modulator

Binds and activates ERRα/β/γ which regulate energy metabolism gene expression. Upregulates PGC-1α (mitochondrial biogenesis master regulator), activates AMPK pathway, increases mitochondrial density to 1.

Half-life: Under investigation (no human PK data) Typical dose: NO HUMAN DOSE ESTABLISHED (animal studies: 50 mg/kg IP) metabolic, longevity
ampk hepatotoxicinsulin disrupting
View full profile

Combined Organ Load

Gonads
low
Pituitary
low
Pancreas
low

Shared Safety Flags

2x 2 hepatotoxic compounds (Enclomiphene, SLU-PP-332). Liver damage risk significantly increased. Include liver support (TUDCA/NAC) and monitor ALT/AST.

Frequently Asked Questions

Can I take Enclomiphene with SLU-PP-332?

Combining Enclomiphene with SLU-PP-332 is not recommended. Both Enclomiphene and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.

Is Enclomiphene and SLU-PP-332 safe together?

This combination carries significant risk. Both Enclomiphene and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. Consult a healthcare professional before combining.

What are the interactions between Enclomiphene and SLU-PP-332?

Both Enclomiphene and SLU-PP-332 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently. This assessment has 53% confidence and is inferred from pharmacological mechanism analysis.

How should I time Enclomiphene and SLU-PP-332?

Enclomiphene has a half-life of ~10 hours and SLU-PP-332 has a half-life of Under investigation (no human PK data). No specific timing requirements identified for this combination, but separating administration can help monitor individual effects.

Check this pair in the full Interaction Checker Full comparison: Enclomiphene vs SLU-PP-332

This interaction analysis is compiled from research literature and pharmacological mechanism data. This assessment is inferred from known mechanisms and may not reflect all real-world outcomes. Always consult a healthcare professional before combining compounds.